

Is the efficacy of remdesivir so different from that of lopinavir–ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review

Tiago Isidoro Duarte¹, Cesar Vieira¹, Carlos Pimentel¹, Mariana Cascão², Marta Torre², Joaquim Santos-Lima², Tânia Sequeira¹, Nuno Germano¹, Rita Corte-Real³, Luís Bento²

¹Polyvalent Intensive Care Unit, Hospital de Curry Cabral, Lisbon, Portugal

²Medical Emergency Unit, Hospital de São José, Lisbon, Portugal

³Department of Clinical Patology, Hospital de Curry Cabral, Lisbon, Portugal

Dear Editor,

This letter discusses the efficacy of current antiviral therapy used in severe COVID-19 infection. Since the first severe cases were documented, several antiviral options have been studied as adjuncts to standard supportive care [1, 2]. Firstly, the combination of lopinavir–ritonavir resurrected from SARS and MERS outbreaks and soon abandoned after the publication of several trials like the randomized controlled trial RECOVERY, which concluded that it was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progression to invasive mechanical ventilation or death [3]. Remdesivir is currently the only antiviral agent approved for the treatment of COVID-19. It is recommended for use in hospitalized patients who require supplemental oxygen. However, it is not routinely recommended for patients who require mechanical ventilation due to the lack of data showing any benefit at this advanced stage of the disease [4–6].

We report a multicentre observational study whose aim was to assess the efficacy of these antiviral options

in severe COVID-19 pneumonia using an analysis of the viral load throughout treatment with real-time polymerase chain reaction (PCR). We sequentially included all patients with confirmed COVID-19 infection admitted to the intensive care medicine departments of 2 hospitals in central Lisbon (Portugal) from March to September 2020. Patients were divided into 3 groups according to the clinical protocol in force at their time of admission, as seen in Figure 1. Exclusion criteria were pregnancy, known allergy or hypersensitivity to lopinavir–ritonavir or remdesivir, QT prolongation, alanine aminotransferase or aspartate aminotransferase levels > 5× the upper limit of the normal range or acute kidney injury higher than grade 2 according to KDIGO criteria. Electrocardiogram monitoring (in particular, QT interval), was performed continuously in all patients. SARS-CoV-2 RNA detection was performed by real time-PCR from pharyngeal swabs/endotracheal aspirates using primers for genes *ORF1a*, *N*, and *E*. The number of thermal cycles needed for RNA detection (threshold cycle – Ct) was recorded. RNA viral load

Anaesthesiol Intensive Ther 2021; 53, 4: 363–365

Received: 06.01.2021, accepted: 23.07.2021




FIGURE 1. Study design

CORRESPONDING AUTHOR:

Tiago Isidoro Duarte, Polyvalent Intensive Care Unit, Hospital de Curry Cabral, Lisboa, Portugal, e-mail: tiagomisidoruarte@gmail.com

was indirectly estimated by Ct count and considered undetectable above 40 thermal cycles. Local Ethical Committee and Board Administration, Comissão de Ética para a Saúde e Conselho de Administração do Centro Hospitalar Universitário de Lisboa Central, approved this study and its publication (INV_69_854/2020); written informed consent was waived by the ethics committee.

A total of 128 patients were included in this cohort and divided in 3 groups according to their treatment regimen. Among all cohorts, the majority were male with a high prevalence of more than 2 comorbidities (Table 1), which is in line with the

literature [7]. No relevant differences were found between baseline characteristics among all groups. Time to hospital and intensive care unit (ICU) admission were also similar in all groups. Differences in the need for mechanical ventilation may be due to our early approach and early orotracheal intubation protocol implemented in the first part of this pandemic. Furthermore, as the understanding and knowledge of COVID-19 disease has become more extensive, new options such as high-flow oxygen therapy allow us to reduce the number of invasive mechanical ventilation patients. Time to negative SARS-CoV-2 was slightly lower in the remdesivir group (16 vs.

TABLE 1. Demographic and clinical characteristics

Characteristics	Lopinavir–ritonavir group (n = 52)	Control group (n = 44)	P-value*	Remdesivir group (n = 32)	P-value**
Age (years)	69 (63–75)	64 (61–67)	0.228	66 (64–71)	0.289
Male/Female, n/n	41/11	32/12	0.234	23/9	0.347
Body mass index, kg m ⁻²	27.7 (24.8–29.6)	26.4 (24.2–27.7)	0.287	28.1 (26.0–31.9)	0.195
Coexisting conditions, n (%)					
Hypertension	32 (61.5)	33 (75.0)	0.163	26 (81.2)	0.794
Diabetes mellitus	20 (38.5)	27 (61.4)	0.025	19 (59.4)	0.438
Chronic renal disease	10 (19.2)	15 (34.1)	0.106	14 (43.7)	0.949
COPD	5 (9.6)	14 (31.8)	0.090	10 (31.2)	0.206
Asthma	2 (3.8)	0 (0)	0.159	2 (6.3)	0.161
Obstructive sleep apnoea	5 (9.6)	1 (2.3)	0.143	7 (21.9)	0.090
Heart failure	4 (7.7)	7 (15.9)	0.126	3 (9.4)	0.202
Chronic liver disease	4 (7.7)	2 (4.5)	0.373	1 (3.1)	0.535
Cerebrovascular disease	4 (7.7)	0 (0)	0.127	1 (3.1)	0.117
Cancer	5 (9.6)	0 (0)	0.198	2 (6.3)	0.564
Alcohol abuse	6 (11.5)	1 (2.3)	0.266	1 (3.1)	0.117
Smoking	2 (3.8)	3 (6.8)	0.160	3 (9.4)	0.348
Admission SOFA score	7.5 (6.0–8.0)	7.5 (6.0–8.0)	0.382	8.0 (6.0–10.0)	0.364
Highest SOFA score	8.0 (7.0–11.0)	8.2 (7.0–11.0)	0.506	9.0 (7.0–12.0)	0.474
APACHE II score	17 (13–20)	15 (11–20)	0.498	18 (15–23)	0.835
Time to hospital admission, days	6.8 (4.5–9.8)	6.0 (5.0–6.6)	0.787	5.0 (3.0–8.0)	0.656
Time to ICU admission, days	2 (1–3)	2 (1–3)	0.452	2 (1–3)	0.437
ICU stay, days	13.8 (8.9–17.9)	14.4 (13.4–17.9)	0.676	12.8 (8.0–15.5)	0.276
Time to negative SARS-CoV-2, days	16.0 (12.9–19.3)	14.2 (12.0–16.1)	0.104	14.6 (10.6–17.3)	0.253
Need for invasive mechanical ventilation, n (%)	48 (92,3%)	30 (68,1%)	0.087	23 (71.9%)	0.683
Time under IMV, days	9.7 (7.1–17.4)	8.2 (5.7–14.3)	0.385	13.4 (8.2–19.3)	0.104
Suspended therapy for adverse effects, n (%)	3 (8.8%)	–	–	2 (6.3%)	–
ICU Mortality, number (%)	9 (17.3%)	7 (15.9%)	0.742	10 (31.3%)	0.304
All-cause hospital mortality, number (%)	12 (23.1%)	10 (22.7%)	0.783	10 (22,7%)	0.731

Categorical variables were described as frequency (percentage), and continuous variables as median and interquartile range IQR. Comparisons between groups were performed with χ^2 test or Mann-Whitney test.

All comparisons considered a threshold for statistical significance < 0.05.

*Comparison between lopinavir–ritonavir group and control group. **Comparison between remdesivir group and control group

COPD – chronic obstructive pulmonary disease




FIGURE 2. Number of cycle count for gene detection by real time-PCR

14.6 days for the lopinavir-ritonavir and remdesivir group, respectively). As described by Wang *et al.*, we used cycle threshold values of real-time PCR as indicators of the number of viral copies [8, 9]. When possible, the cycle count for gene detection using real-time PCR was performed using endotracheal aspirates/bronchoalveolar lavage. As seen in Figure 2, before any treatment, the median Ct count was similar in all groups. During treatment the remdesivir group seemed to reach a negative search earlier than lopinavir-ritonavir and control groups, as can be seen with a progressively higher cycle count number (Figure 2). This conclusion was identical to those described by Cao *et al.* [10], and was in line with the multicentre trial developed by Wang *et al.* [11] in which remdesivir did not provide significant clinical or antiviral effects in seriously ill patients with COVID-19. ICU mortality was higher in the remdesivir group (31.3%).

Managing SARS-CoV-2-infected patients has truly been a medical challenge. Despite the global vaccination program in course, we suggest that it is important not to lose the focus on antiviral therapy because it can have the greatest impact before the illness progresses into the hyperinflammatory state that can characterize the

later stages of disease, including critical illness.

ACKNOWLEDGMENTS

1. Financial support and sponsorship: none.
2. Conflicts of interest: none.

REFERENCES

1. Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y, Timsit JF. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. *Intensive Care Med* 2020; 46: 579-582. doi: 10.1007/s00134-020-05967-x.
2. Ali MJ, Hanif M, Haider MA, et al. Treatment options for COVID-19: a review. *Front Med (Lausanne)* 2020; 7: 480. doi: 10.3389/fmed.2020.00480.
3. Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2020; 396: 1345-1352. doi: 10.1016/S0140-6736(20)32013-4.
4. Beigel J, Tomashek K, Finberg RW, et al. Remdesivir for the treatment of Covid-19 – final report. *N Engl J Med* 2020; 383: 1813-1826. doi: 10.1056/NEJMoa2007764.
5. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 a randomized clinical trial. *JAMA* 2020; 324: 1048-1057. doi: 10.1001/jama.2020.16349.
6. Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. *N Engl J Med* 2020; 383: 1827-1837. doi: 10.1056/NEJMoa2015301.
7. Ayed M, Borahmah AA, Yazdani A, Sultan A, Mossad A, Rawdhan H. Assessment of clinical characteristics and mortality-associated factors in COVID-19 critical cases in Kuwait. *Med Princ Pract* 2021; 30: 185-192.
8. Wang W, Xu Y, Gao R. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA* 2020; 323: 1843-1844. doi: 10.1001/jama.2020.3786.
9. Yu F, Yan L, Wang N, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. *Clin Infect Dis* 2020; 71: 793-798. doi: 10.1093/cid/ciaa345.
10. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. *N Engl J Med* 2020; 382: 1787-1799. doi: 10.1056/NEJMoa2001282.
11. Wang Y, Zhang D, Du G, Du R, Jin Y. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; 395: 1569-1578. doi: 10.1016/S0140-6736(20)31022-9.